Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
948 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02381886 | A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations | active not recruiting | Phase 1 | 166 | Novartis PharmaceuticalsINDUSTRY | 8 | Apr 13, 2026 | clinicaltrials |
| NCT05038631 | Managed Access Programs for LEE011, Ribociclib | available | — | — | Novartis PharmaceuticalsINDUSTRY | 0 | Apr 13, 2026 | clinicaltrials |
| NCT07512063 |
| A Study of Real-World Treatment Patterns and Outcomes Among HR+/HER2- Metastatic Breast Cancer Patients Treated With First-Line CDK4/6 Inhibitors |
| completed |
| — |
| 480 |
| Novartis PharmaceuticalsINDUSTRY |
| 1 |
| Apr 13, 2026 |
| clinicaltrials |
| NCT05110196 | Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC. | completed | Phase 4 | 50 | Novartis PharmaceuticalsINDUSTRY | 1 | Apr 7, 2026 | clinicaltrials |
| NCT07476170 | Real-World Treatment Pattern and Clinical Outcome With Influential Factors of HR+/HER2-aBC 1L Patients in China | recruiting | — | 14,000 | Novartis PharmaceuticalsINDUSTRY | 1 | Apr 2, 2026 | clinicaltrials |
| NCT03798626 | Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers | completed | Phase 1 | 167 | Novartis PharmaceuticalsINDUSTRY | 15 | Apr 1, 2026 | clinicaltrials |
| NCT04903197 | Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma | terminated | Phase 1 | 18 | Novartis PharmaceuticalsINDUSTRY | 7 | Apr 1, 2026 | clinicaltrials |
| NCT05100134 | Managed Access Programs for LDK378, Ceritinib | no longer available | — | — | Novartis PharmaceuticalsINDUSTRY | 0 | Apr 1, 2026 | clinicaltrials |
| NCT05868629 | Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors | recruiting | — | 40 | Novartis PharmaceuticalsINDUSTRY | 1 | Apr 1, 2026 | clinicaltrials |
| NCT06625333 | A Prospective Non-interventional Study to Evaluate Clinical Outcomes of Ribociclib Combined With Endocrine Therapy in Elderly Patients With HR+HER2 - Advanced Breast Cancer in Routine Clinical Practice in Russian Federation(PARFENOPA) | active not recruiting | — | 329 | Novartis PharmaceuticalsINDUSTRY | 1 | Apr 1, 2026 | clinicaltrials |
| NCT07375355 | Real-world Study of Scemblix in the Treatment of Chronic Myeloid Leukemia in China(ASC4CN) | recruiting | — | 200 | Novartis PharmaceuticalsINDUSTRY | 1 | Apr 1, 2026 | clinicaltrials |
| NCT07498413 | Epidemiology and Treatment of HR+/HER2- Breast Cancer in England(ROTOR) | completed | — | 218,677 | Novartis PharmaceuticalsINDUSTRY | 1 | Apr 1, 2026 | clinicaltrials |
| NCT04677595 | Study of Capmatinib in Chinese Adult Patients With Advanced Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation(GeoMETry-C) | completed | Phase 2 | 36 | Novartis PharmaceuticalsINDUSTRY | 1 | Mar 31, 2026 | clinicaltrials |
| NCT07290270 | Real-world Use of Lutetium (177Lu) Vipivotide Tetraxetan in China(PSMAreal CN)(PSMAreal) | recruiting | — | 170 | Novartis PharmaceuticalsINDUSTRY | 1 | Mar 30, 2026 | clinicaltrials |
| NCT05838768 | Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency. | active not recruiting | Phase 1 | 123 | Novartis PharmaceuticalsINDUSTRY | 15 | Mar 24, 2026 | clinicaltrials |
| NCT05658003 | A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer | active not recruiting | Phase 2 | 63 | Novartis PharmaceuticalsINDUSTRY | 1 | Mar 23, 2026 | clinicaltrials |
| NCT07484269 | PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan(PULSE) | not yet recruiting | — | 753 | Novartis PharmaceuticalsINDUSTRY | 0 | Mar 20, 2026 | clinicaltrials |
| NCT07477756 | A Real-world Study of Characteristics, Treatment Patterns, and Clinical Outcomes Among Lutetium-177 Vipivotide Tetraxetan Treated Patients | completed | — | 1,247 | Novartis PharmaceuticalsINDUSTRY | 1 | Mar 19, 2026 | clinicaltrials |
| NCT04699188 | Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation(KontRASt-01) | active not recruiting | Phase 1 / Phase 2 | 344 | Novartis PharmaceuticalsINDUSTRY | 16 | Mar 18, 2026 | clinicaltrials |
| NCT04948333 | Asciminib Treatment Optimization in ≥ 3rd Line CML-CP | completed | Phase 3 | 199 | Novartis PharmaceuticalsINDUSTRY | 16 | Mar 18, 2026 | clinicaltrials |
| NCT04741789 | Managed Access Programs for INC280, Capmatinib | no longer available | — | — | Novartis PharmaceuticalsINDUSTRY | 0 | Mar 16, 2026 | clinicaltrials |
| NCT05697146 | Ribociclib Real-world Treatment Patterns and Clinical Outcomes Among Women With HR+/HER2- Advanced or Metastatic Breast Cancer in France(RosaLEE) | active not recruiting | — | 1,019 | Novartis PharmaceuticalsINDUSTRY | 1 | Mar 16, 2026 | clinicaltrials |
| NCT04417621 | Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma | active not recruiting | Phase 2 | 134 | Novartis PharmaceuticalsINDUSTRY | 12 | Mar 12, 2026 | clinicaltrials |
| NCT07450157 | A Study of Patient Characteristics, Treatment Patterns and Outcomes Among Patients Treated With 177Lu-PSMA-617 | completed | — | 6,448 | Novartis PharmaceuticalsINDUSTRY | 1 | Mar 4, 2026 | clinicaltrials |
| NCT04895748 | DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies | terminated | Phase 1 | 40 | Novartis PharmaceuticalsINDUSTRY | 7 | Mar 3, 2026 | clinicaltrials |
| NCT05022342 | Study of PIK3CA Mutations and Effectiveness and Tolerability Outcomes of Alpelisib in Real-world(SPEAR) | completed | — | 595 | Novartis PharmaceuticalsINDUSTRY | 1 | Feb 23, 2026 | clinicaltrials |
| NCT04666272 | Effectiveness and Safety of Dabrafenib in Combination With Trametinib as Adjuvant Treatment for Chinese Patients With Stage III BRAF V600 Mutation-positive Melanoma After Complete Resection | active not recruiting | — | 78 | Novartis PharmaceuticalsINDUSTRY | 1 | Feb 19, 2026 | clinicaltrials |
| NCT05462873 | A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumors | terminated | Phase 1 | 30 | Novartis PharmaceuticalsINDUSTRY | 9 | Feb 17, 2026 | clinicaltrials |
| NCT06240741 | A Prospective, Open-label Study of [68Ga]Ga-DOTA-TATE in Patients With Neuroendocrine Neoplasms (NENs) and Healthy Volunteers in Japan | completed | Phase 3 | 71 | Novartis PharmaceuticalsINDUSTRY | 1 | Feb 3, 2026 | clinicaltrials |
| NCT07374120 | Treatment Patterns and Key Endpoints Among Patients With Chronic-Phase Chronic Myeloid Leukemia in a Community Oncology Setting | completed | — | 1,480 | Novartis PharmaceuticalsINDUSTRY | 1 | Feb 2, 2026 | clinicaltrials |
| NCT07363434 | A Real-world Study of Indian Patients With Advanced Breast Cancer Treated With Ribociclib(RESONATE) | completed | — | 335 | Novartis PharmaceuticalsINDUSTRY | 1 | Jan 23, 2026 | clinicaltrials |
| NCT03891953 | Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors. | active not recruiting | Phase 1 | 98 | Novartis PharmaceuticalsINDUSTRY | 6 | Jan 21, 2026 | clinicaltrials |
| NCT03333343 | Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC | active not recruiting | Phase 1 | 105 | Novartis PharmaceuticalsINDUSTRY | 6 | Jan 16, 2026 | clinicaltrials |
| NCT03056755 | Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments(BYLieve) | completed | Phase 2 | 383 | Novartis PharmaceuticalsINDUSTRY | 19 | Jan 13, 2026 | clinicaltrials |
| NCT04150029 | A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for Chemotherapy(STIMULUS-AML1) | terminated | Phase 2 | 90 | Novartis PharmaceuticalsINDUSTRY | 10 | Jan 13, 2026 | clinicaltrials |
| NCT04266301 | Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)(STIMULUS-MDS2) | terminated | Phase 3 | 530 | Novartis PharmaceuticalsINDUSTRY | 36 | Jan 13, 2026 | clinicaltrials |
| NCT04452877 | A Study of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutant Metastatic NSCLC | completed | Phase 2 | 40 | Novartis PharmaceuticalsINDUSTRY | 1 | Jan 13, 2026 | clinicaltrials |
| NCT05172596 | PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma | terminated | Phase 2 | 146 | Novartis PharmaceuticalsINDUSTRY | 14 | Jan 13, 2026 | clinicaltrials |
| NCT06236061 | Study of Efficacy and Safety of LCZ696/Amlodipine in Grade 1 and 2 Hypertension Patients Uncontrolled by LCZ696 Monotherapy | completed | Phase 3 | 718 | Novartis PharmaceuticalsINDUSTRY | 1 | Jan 13, 2026 | clinicaltrials |
| NCT05544929 | A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers | active not recruiting | Phase 1 | 126 | Novartis PharmaceuticalsINDUSTRY | 12 | Jan 6, 2026 | clinicaltrials |
| NCT06531499 | A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study(RADIODOSE) | recruiting | Phase 1 | 106 | Novartis PharmaceuticalsINDUSTRY | 6 | Dec 31, 2025 | clinicaltrials |
| NCT06881823 | Study to Assess [177Lu]Lu-PSMA-R2 (AAA602) and [225Ac]Ac-PSMA-R2 (AAA802) in Participants With PSMA-positive HRLPC(NeoPSMA) | withdrawn | Phase 1 / Phase 2 | 0 | Novartis PharmaceuticalsINDUSTRY | 0 | Dec 29, 2025 | clinicaltrials |
| NCT04123418 | A Study of WVT078 in Patients With Multiple Myeloma (MM) | terminated | Phase 1 | 56 | Novartis PharmaceuticalsINDUSTRY | 8 | Dec 24, 2025 | clinicaltrials |
| NCT04294160 | A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer | terminated | Phase 1 | 122 | Novartis PharmaceuticalsINDUSTRY | 10 | Dec 24, 2025 | clinicaltrials |
| NCT05977322 | A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors. | terminated | Phase 1 | 24 | Novartis PharmaceuticalsINDUSTRY | 4 | Dec 24, 2025 | clinicaltrials |
| NCT06684964 | RWE,NIS,Prospective Study for the Effectiveness, Tolerability and Adherence of Asciminib in Saudi Arabia. (ASC4REAL)(ASC4REAL) | recruiting | — | 40 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 23, 2025 | clinicaltrials |
| NCT05844332 | LUTATHERA Injection General Use Result Survey | completed | — | 347 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 22, 2025 | clinicaltrials |
| NCT04489433 | Compassionate Use Program to Access Trametinib and Dabrafenib for Patients With BRAF Mutation-positive Metastatic Melanoma | no longer available | — | — | Novartis PharmaceuticalsINDUSTRY | 0 | Dec 18, 2025 | clinicaltrials |
| NCT04961619 | Adjuvant Dabrafenib and Trametinib Treatment in Patients With Completely Resected High-risk Stage III Melanoma.(LEAD Melanoma) | completed | — | 39 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 12, 2025 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials